Last reviewed · How we verify

Jiangsu vcare pharmaceutical technology co., LTD — Portfolio Competitive Intelligence Brief

Jiangsu vcare pharmaceutical technology co., LTD pipeline: 0 marketed, 0 filed, 6 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 2 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vicagrel Vicagrel phase 3 Other
VC005 Tablets VC005 Tablets phase 3 SGLT2 inhibitor SGLT2 Diabetes
VC005 low dose group VC005 low dose group phase 3 SGLT2 inhibitor SGLT2 Diabetes
VC005 VC005 phase 3 SGLT2 inhibitor SGLT2 Diabetes
VC005 high dose group VC005 high dose group phase 3 SGLT2 inhibitor SGLT2 Diabetes
VC004 Capsules VC004 Capsules phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ADvantage Therapeutics · 1 shared drug class
  2. AJU Pharm Co., Ltd. · 1 shared drug class
  3. AO GENERIUM · 1 shared drug class
  4. Abbott · 1 shared drug class
  5. AceLink Therapeutics, Inc. · 1 shared drug class
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. Aciex Therapeutics, Inc. · 1 shared drug class
  8. 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu vcare pharmaceutical technology co., LTD:

Cite this brief

Drug Landscape (2026). Jiangsu vcare pharmaceutical technology co., LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-vcare-pharmaceutical-technology-co-ltd. Accessed 2026-05-18.

Related